Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?

Abstract

BACKGROUND\nScaffold thromboses (ST) and adverse events and have been associated with bioresorbable vascular scaffolds (BVS) at long-term, but their mechanism remains unclear. We sought to evaluate patient and lesion characteristics associated with mid- to long-term outcomes in patients treated with BVS.\n\n\nMETHODS\nThis is an observational single-center, single-arm, retrospective study evaluating the performance of BVS in an all-comer population, including complex lesions (chronic total occlusions, long lesions), small vessels, and acute coronary syndromes (ACS).\n\n\nRESULTS\nFrom May 2013 to June 2015, we included 482 patients (580 lesions) that were treated with BVS implantation including 71.2% treated for ACS in the present analysis. Mean follow-up period was 816.2\u202f±\u202f242.6\u202fdays. The primary endpoint was device oriented cardiac events (DOCE), defined as a composite of target-lesion revascularization (TLR), ST, target vessel myocardial infarction (TVMI) and cardiac death. Using Kaplan-Meier methods, the DOCE and ST rates at 36\u202fmonths were 9.4% and 2.3%, respectively. No ST occurred between 2 and 3\u202fyears and ST occurred after 3\u202fyears, in one patient. Using multivariate analysis, ACS was the only significant predictor of lower rates of DOCE (p\u202f=\u202f0.04, HR: 0.47, 95% CI: 0.23-0.96).\n\n\nCONCLUSIONS\nIn this large all-comers real-world cohort, lesions treated with BVS had non-negligible rates of DOCE and ST, in line with previous published randomized trials. The occurrence of very late event was very low after 24\u202fmonths. ACS patients had lower rates of DOCE.